Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Zocor

- PMLiVE

Merck wins speedy FDA review for 15-valent pneumococcal vaccine

Pfizer's rival 20-valent candidate was granted priority review in December 2020

- PMLiVE

Keytruda claims first blood cancer OK from FDA

Merck & Co wins US approval for its haematological cancer treatment

- PMLiVE

Merck & Co buys IOmet to boost immuno-oncology tech

Reports suggest it paid up to £280m for the Scottish biopharma company

- PMLiVE

FDA panel rejects cardiovascular outcomes claim for Vytorin

Merck & Co fail to convince regulator's advisors

- PMLiVE

Merck and Lilly enter Keytruda collaboration

Will research anti-PD-1 cancer therapy as part of combination treatment

- PMLiVE

Medical device M&A hit ‘all-time high’ in 2014

Deals last year were led by Medtronic’s acquisition of Covidien

- PMLiVE

UPDATE: Merck to acquire Cubist for $8.4bn

Will expand company's presence in antibiotics

- PMLiVE

Merck files once-weekly DPP-4 inhibitor in first market

Picks Japan to submit omarigliptin

- PMLiVE

Merck buys rights to NewLink’s Ebola vaccine

Drug is set to enter large phase III study in early 2015

- PMLiVE

Merck’s ezetimibe has ‘modest’ benefit when added to statins

Combination showed a reduction in cardiovascular events in patients with ACS

- PMLiVE

Merck & Co’s cancer drug Keytruda gaining traction in US

Anti-PD-1 drug is used in around three quarters of eligible patients in US just weeks after FDA approval

- PMLiVE

Nimbus looks to Merck for CEO

Donald Nicholson spent 26 years at US pharma giant

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links